Wednesday, 5 November, 2025
Femasys Stock Surges on FDA Final Trial Approval for FemBloc Birth Control
Femasys stock saw a retail trading spike after the FDA approved the final phase of its pivotal trial for FemBloc, its non-surgical, permanent birth control device. This regulatory win, coupled with a $12 million financing deal that could reach $58 million through warrants, strengthens the company's path toward US market approval. The news has retail investors calling the women's health technology a strong long-term growth play.
Read full story at Stock Twits